Iradimed Corporation (NASDAQ:IRMD – Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 74,400 shares, an increase of 8.9% from the September 15th total of 68,300 shares. Based on an average daily volume of 49,800 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.9% of the company’s stock are short sold.
Analyst Ratings Changes
Separately, Roth Mkm dropped their price target on Iradimed from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd.
Check Out Our Latest Report on IRMD
Iradimed Stock Performance
Iradimed (NASDAQ:IRMD – Get Free Report) last issued its earnings results on Thursday, August 1st. The medical equipment provider reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.05. Iradimed had a net margin of 26.83% and a return on equity of 24.71%. The business had revenue of $17.93 million during the quarter, compared to analysts’ expectations of $17.70 million. During the same period in the previous year, the company earned $0.33 earnings per share. Research analysts anticipate that Iradimed will post 1.41 earnings per share for the current fiscal year.
Iradimed Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 30th. Investors of record on Tuesday, August 20th were issued a $0.15 dividend. The ex-dividend date of this dividend was Tuesday, August 20th. This represents a $0.60 annualized dividend and a yield of 1.16%. Iradimed’s payout ratio is 42.55%.
Hedge Funds Weigh In On Iradimed
Several hedge funds and other institutional investors have recently bought and sold shares of IRMD. Isthmus Partners LLC raised its holdings in shares of Iradimed by 880.8% during the first quarter. Isthmus Partners LLC now owns 71,905 shares of the medical equipment provider’s stock valued at $3,163,000 after purchasing an additional 64,574 shares during the last quarter. Liontrust Investment Partners LLP purchased a new stake in Iradimed during the second quarter valued at $2,830,000. Roubaix Capital LLC bought a new position in Iradimed in the first quarter valued at about $2,213,000. Kings Path Partners LLC purchased a new position in shares of Iradimed in the second quarter worth approximately $1,055,000. Finally, Sequoia Financial Advisors LLC purchased a new position in shares of Iradimed during the 2nd quarter worth $568,000. Institutional investors own 92.34% of the company’s stock.
About Iradimed
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
Further Reading
- Five stocks we like better than Iradimed
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Transportation Stocks Investing
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.